A Canadian perspective on bendamustine for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.

@article{Jagt2012ACP,
  title={A Canadian perspective on bendamustine for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.},
  author={Richard Van der Jagt and Pierre Laneuville and Deborah Macdonald and Douglas M Stewart and Anna L Christofides and Laurie H. Sehn},
  journal={Current oncology},
  year={2012},
  volume={19 3},
  pages={160-8}
}
Despite the success of standard treatments in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), patients are often unable to tolerate aggressive regimens, and they require effective alternatives. Bendamustine is a bifunctional alkylator with unique properties that significantly distinguish it from other agents in its class. In untreated CLL, bendamustine has demonstrated rates of response and progression-free survival (PFS) that are superior to those with chlorambucil, with an… CONTINUE READING